Background Human papillomavirus (HPV) vaccination programmes were fi rst implemented in several countries worldwide in 2007. We did a systematic review and meta-analysis to assess the population-level consequences and herd eff ects after female HPV vaccination programmes, to verify whether or not the high effi cacy reported in randomised controlled clinical trials are materialising in real-world situations.
Introduction
Since 2007, 52 out of 195 countries worldwide have implemented human papillomavirus (HPV) vaccination programmes, including 41% of high-income countries and 15% of low-income and middle-income countries.
1-4
The population-level eff ect of HPV vaccination programmes is expected to vary substantially between these countries, depending on the vaccine used, implementation strategies, and vaccination coverage achieved. Two HPV vaccines are currently available worldwide: the bivalent vaccine, which targets HPV types 16 and 18 (which are associated with 70-80% of cervical cancers globally 5 ), and the quadrivalent vaccine, which also targets HPV types 6 and 11 (associated with 85-95% of cases of anogenital warts 6 ). Most high-income countries are using the quadrivalent vaccine, whereas a mixed picture exists for low-income and middle-income countries.
2,7 Although all HPV vaccination programmes target pre-adolescent girls (and might also include catchup programmes for older girls and women), a few countries, such as the USA and Australia, have recently begun to include boys. 8, 9 Finally, in high-income countries, vaccination coverage in the younger cohorts of girls ranges from nearly 90% to less than 50%, mostly depending on whether the countries have school-based or non-school-based vaccination programmes. 10 Large international randomised controlled clinical trials have shown both HPV vaccines to be safe and well tolerated, highly effi cacious against vaccine-type persistent HPV infection and precancerous cervical lesions in women (vaccine effi cacy 93-100%), 11, 12 and to provide some degree of cross-protection against three non-vaccine types (HPV types 31, 33, and 45), [12] [13] [14] which are associated with 10-15% of cervical cancers worldwide. 15 Existing evidence from clinical trials also suggests that cross-protective vaccine effi cacy estimates against infections and lesions associated with HPV types 31, 33, and 45 are higher for the bivalent vaccine than for the quadrivalent vaccine. 16 Following clinical trials, mathematical models have been used to predict the long-term population-level eff ectiveness and cost-eff ectiveness of vaccination programmes delivered in diff erent settings. Modelling studies have con sistently predicted that the overall burden of HPVrelated diseases in women will decrease substantially in the next few decades through vaccination, and that vaccination of girls against HPV is highly cost eff ective in most countries. [17] [18] [19] Despite consistency in model predictions of the direct eff ects of HPV vaccination in vaccinated girls, uncertainty remains about the potential population-level eff ects of cross-protection and herd protection (eg, the indirect consequences of vaccinating girls on HPV in unvaccinated boys, men, and adult women), and the vaccination coverage necessary to achieve substantial herd eff ects. [20] [21] [22] [23] [24] This information is crucial to help guide vaccine choices and inform decisions about vaccination of boys and men.
Now that more than 7 years have elapsed since the implementation of the fi rst HPV vaccination programmes in 2007 (appendix pp 2-4), it is timely to verify whether or not the promising results from clinical trials and model projections are materialising at the population level. An increasing number of post-vaccination surveillance studies have recently been published using several intermediate endpoints (eg, HPV infection, anogenital warts, and precancerous cervical lesions). The aim of this systematic review and meta-analysis is to summarise existing evidence about the population-level eff ect of HPV vaccination, as measured in time-trend studies in girls and young women targeted for vaccination, and in boys, men, and older women. We focused on three HPV-related endpoints: HPV infection, anogenital warts, and high-grade cervical lesions.
Methods

Search strategy and selection criteria
We systematically reviewed the global literature and report it in accordance with the PRISMA guidelines. 25 Studies were eligible for inclusion if they fulfi lled the following criteria: they provided data about at least one endpoint of HPV infection, anogenital warts, histopathologically confi rmed high-grade cervical lesions (cervical intraepithelial neoplasia [CIN] 2 or worse); if they assessed the population-level eff ect by comparing the frequency (prevalence or incidence) of the endpoint between the pre-vaccination and post-vaccination periods (ie, time-trend studies); and if data from the prevaccination and post-vaccination periods were collected from the same population sources with use of the same recruitment methods.
We excluded studies with the following characteristics because they did not measure population-level eff ect: if HPV vaccination was administered as part of an individual-based randomised trial, or HPV vaccination eff ect was assessed by comparing the frequency of the endpoint between vaccinated and unvaccinated people during the post-vaccination period.
Our search strategy had three stages. First, we searched the Medline and Embase databases between Jan 1, 2007, and Feb 28, 2014 , with a combination of the following Medical Subject Heading (MeSH) terms, title, or abstract words, with no restriction on the language of publication: ("papillomavirus vaccine", "papillomavirus vaccination", "HPV vaccine", or "HPV vaccination") and ("program evaluation", "population surveillance", "sentinel surveillance", "incidence", or "prevalence"), and ("papillomavirus infection", "condylomata acuminata", "anogenital warts", "cervical intraepithelial neoplasia", "cervical dysplasia", "uterine cervical neoplasm", or "HPV related diseases"). We identifi ed eligible studies by reviewing titles and abstracts, and we also searched the reference lists of eligible articles. Second, we reviewed the abstracts of recent major conferences on HPV (the European Research Organisation on Genital Infection and Neoplasia [EUROGIN] Congress 2013 and the International Papillomavirus Conference 2012) to identify additional unpublished studies. Third, MD and MB contacted the authors of conference abstracts to obtain unpublished data. MD and EB independently assessed the eligibility of all studies. Additionally, DM independently assessed the eligibility of studies of HPV infection. If more than one publication from the same data source and research team was available, we kept the publication that presented the most recent data.
Data extraction and quality assessment
Our primary outcomes were the relative risks (RR) comparing the pre-vaccination and post-vaccination periods for: the prevalence of HPV infection for four HPV type subgroups (high-oncogenic risk vaccine types [HPV16 and HPV18], three types with the greatest evidence of cross-protective effi cacy [HPV31, HPV33, and HPV45], 16 the fi ve potentially cross-protective types [HPV31, HPV33, HPV45, HPV52, and HPV58], 16 and all high-oncogenic risk non-vaccine types [all high-risk HPV types except for HPV16 and HPV18]); the frequency (prevalence or incidence) of anogenital wart diagnosis; and the frequency (prevalence or incidence) of high-grade cervical lesions. Two authors (MD and EB) independently extracted the study characteristics and outcomes using a standardised form. MD and MB contacted authors to request supplementary extractions to standardise data stratifi cations between studies for comparison and pooling (eg, same age and HPV type groupings). We also collected information about the vaccination programme characteristics and vaccination coverage of the country or region of each study (appendix pp 2-4). For the HPV prevalence studies, we collected age-specifi c vaccination coverage directly from each study, since vaccination status was available for all study participants. Finally, the authors of each article validated the data from their study.
Before contacting the study investigators, MD, AM, PLM, and MB assessed whether or not the studies had suffi cient methodological quality to be included in the meta-analysis. The quality of the studies (potential for bias and confounding, and external validity) was assessed independently from the investigators of the original studies. Potential for bias and confounding within studies were assessed by review of the participant selection or recruitment procedures, endpoint defi nitions, algorithms used to identify cases, and potential confounders con sidered in the statistical analyses (appendix pp 5-9).
Data analysis
Because mostly girls (<20 years of age) were vaccinated in the study populations, we decided a priori to stratify all our analyses by sex and age. Furthermore, because only the quadrivalent vaccine includes HPV types 6 and 11 (which are responsible for roughly 90% of cases of anogenital warts 6 ), we decided a priori to stratify our analyses for anogenital warts by the type of vaccine.
To ensure comparability of the study results included in the meta-analysis, we fi rst defi ned pre-vaccination and post-vaccination periods for all studies (appendix pp 10-11). Second, for comparability, we used prevalence or incidence rate ratios as the measure of eff ect for all HPV-related endpoints. For HPV infection, most studies presented RR (crude and/or adjusted prevalence ratios) and 95% CIs. When available, we included adjusted RR in the metaanalysis. When only crude HPV prevalence over time was available, we calculated prevalence ratios by dividing the post-vaccination and pre-vaccination prevalence and estimated the 95% CI (CI approximation for prevalence ratios 26 ). For anogenital warts and precancerous lesions, all studies presented annual frequency (prevalence or incidence) over time. We estimated pre-vaccination frequency by aggregating the data for up to 3 years before vaccination, and calculated RR by dividing each post-vaccination year by the pre-vaccination estimate.
We derived summary estimates of the eff ect of HPV vaccination for each endpoint by using random-eff ects models on the log scale. 27, 28 We did a subgroup analysis to identify potential sources of heterogeneity by comparing the summary estimates obtained from subsets of studies or groups within studies grouped by: vaccine type (bivalent or quadrivalent), vaccination coverage (low <50% or high ≥50%-we used study-specifi c coverage estimates for HPV infection, and country/region-level coverage for the other outcomes), age (<20, 20-24, 25- or 30-39 years), years since the vaccination programme was implemented (1, 2, 3, or 4 years), source of study data (population based, health provider/insurance based, or clinic based), and by whether or not the impact measure was adjusted (yes or no). We examined heterogeneity across studies using I² and χ² statistics. 28 I² values less than 50% represent low heterogeneity, between 50-75% substantial heterogeneity, and more than 75% high heterogeneity. 29 The p value associated with the χ² statistic represents the statistical signifi cance of heterogeneity. Finally, we analysed the dose-response association between HPV vaccination coverage (independent variable) and the log-RR of each study (dependent variable) by fi tting a linear regression, weighted by the inverse variances of the log-RR. 30 We used Review Manager 5.2 and SAS 9.4 for all analyses.
Role of the funding source
The funders had no role in the study design, data collection, analysis and interpretation, or writing of the report. MB had full access to all the data in the study and had fi nal responsibility for the decision to submit for publication.
Results
In our searches we identifi ed 661 articles and 29 conference abstracts, of which 20 records met the inclusion criteria (seven on HPV infection, 31-37 11 on anogenital warts, [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] and two on high-grade cervical lesions; 49, 50 fi gure 1, table). The studies were done in nine highincome countries (the USA, Australia, England, Scotland, New Zealand, Sweden, Denmark, Canada, and Germany) and assessed the population-level consequences of vaccination in 16 600 women for HPV infection, more than 125 million person-years of follow-up for anogenital warts, and 15 million female-years of follow-up for highgrade cervical lesions (table) . The vaccine used, vaccination strategy, delivery, and vaccination coverage varied substantially (table and appendix pp 2-4). All studies had suffi cient methodological quality to be included in the meta-analysis (appendix pp 5-9). However, because two studies analysed the entire Danish population during OR=odds ratio. HPV=human papillomavirus. RR=relative risk (post-vaccination prevalence or incidence/pre-vaccination prevalence or incidence). CIN=cervical intraepithelial neoplasia. *Data sources are regarded as population based when the study population includes the entire population of a given country or region; health provider or insurance based when the study population consists of a subgroup of the total population participating in a specifi c health programme or insurance plan; and clinic based when the study population comprises a fi nite number of clinics or hospital's clients. †For studies of HPV infection, the pre-vaccination and post-vaccination periods were already established in the original publications (except for Kavanagh et al 37 ). For studies of anogenital warts and cervical lesions, the pre-vaccination and post-vaccination periods were established for the purpose of this systematic review as described in appendix pp 10-11. ‡The sample size is restricted to the age groups used in the review. For studies of HPV infection, the pre-vaccination and post-vaccination sample sizes were already established in the original studies. For studies of anogenital warts and cervical lesions, the pre-vaccination sample size corresponds to the cumulative number of personyears up to 3 years pre-vaccination, including the year of the introduction of HPV vaccination. The post-vaccination sample size corresponds to the cumulative number of person-years from 1-4 years after the introduction of vaccination, depending on the data available in each study. §For HPV infection, the investigators recalculated the RR of prevalence using the original data from their specifi c studies. For anogenital warts and precancerous lesions, we estimated pre-vaccination frequency by aggregating the data for up to three years before vaccination, and calculated RR by dividing each post-vaccination year by the prevaccination estimate. ¶13 high-risk HPV types were presented in the original publications, whereas the 18 high-risk HPV types available were used for the purposes of this meta-analysis. || Data from this study are restricted to the Victorian registry data. Supplementary data from the Australian Institute of Health and Welfare 2013 report 51 were provided by Brotherton (JML Brotherton, National HPV Vaccination Program Register, Victorian Cytology Service, East Melbourne, Melbourne, VIC, Australia, personal communication). Since the report covers all regions of Australia, we used it as our main data source for the review. 34 Mesher et al (2013) 35 Sonnenberg et al (2013) 36 Kahn et al (2012) 32 Tabrizi et al (2012) 33 Cummings et al (2012) 31 Kavanagh et al (2014) 37 Overall
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0·50 (0·34-0·74) 0·47 (0·35-0·63) 0·39 (0·19-0·79) 0·38 (0·25-0·58) 0·04 (0·01-0·15) 0·32 (0·12-0·89) NA † 0·36 (0·25-0·53); I 2 =65%, p=0·01 p value for trend=0·005
NA † 0·72 (0·54-0·96); I 2 =0%, p=0·44 p value for trend=0·14
NA † 0·94 (0·79-1·13); I 2 =15%, p=0·32 p value for trend=0·69
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NA † 0·69 (0·47-1·01); I 2 =88%, p<0·00001 p value for trend=0·01 (0·70-1·23) ; I 2 =58%, p=0·04 p value for trend=0·63 
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0·95 (0·75-1·20) 1·29 (1·13-1·47) 0·79 (0·60-1·03) 1·15 (0·99-1·33) 1·15 (0·94-1·41) 0·90 (0·73-1·10) 0·69 (0·47-1·01) 0·57 (0·22-1·45) 0·81 (0·58-1·14) 0·96 (0·77-1·18) 0·42 (0·16-1·10) 0·57 (0·22-1·47) 0·80 (0·58-1·11)
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0·58 (0·46-0·72) 0·54 (0·49-0·60) 0·19 (0·15-0·24) 0·69 (0·60-0·79); I 2 =97%, p<0·00001 p value for trend=0·0007 (0·79-1·02) ; I 2 =99%, p<0·00001 p value for trend=0·05 (0·84-1·08) ; I 2 =93%, p<0·00001 p value for trend=0·005 
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Low female coverage (<50%) § Leval et al (2012) 41 Kliewer et al (2012) 40 Flagg et al (2013) 45 Nsouli-Maktabi et al (2013) 47 Bauer et al (2012) 39 Mikolajczyk et al (2013) 46 High female coverage (≥50%) § Oliphant and Perkins (2011) 38 Baandrup et al (2013) 43 Ali et al (2013) . §Studies were ranked qualitatively by the national or setting-specifi c vaccination coverage, for which we considered the number of cohorts vaccinated and vaccination coverage achieved in each cohort. However, we could not estimate the overall vaccination coverage for each study (see appendix pp 2-4 for details about the programme description, number of cohorts vaccinated, and three-dose vaccination coverage for each study).
identical time periods, 43, 48 we only included Baandrup and colleagues' study 43 in our main analysis (the choice of study had no eff ect on our results; appendix pp [12] [13] [14] .
In girls 13-19 years of age, the overall prevalence of HPV types 16 and 18 decreased signifi cantly by 64% in the post-vaccination period (RR 0·36 [95% CI 0·25-0·53]) compared with the pre-vaccination period (fi gure 2A), with a signifi cant dose-response association with vaccination coverage (p=0·005). The overall prevalence of HPV types 31, 33, and 45 also decreased signifi cantly post-vaccination by 28% (RR 0·72 [95% CI 0·54-0·96]), but the reductions were not associated with vaccination coverage. The overall prevalence of HPV types 31, 33, 45, 52, and 58, and non-vaccine high-risk types (ie, all highrisk HPV types except HPV16 and HPV18) did not change signifi cantly between the pre-vaccination and postvaccination periods (fi gure 2A).
In women 20-24 years of age, the overall prevalence of HPV types 16 and 18 decreased by 31% (RR 0·69 [95% CI 0·47-1·01]) in the post-vaccination period (fi gure 2B). Although the overall reduction in HPV16 and HPV18 infection was not signifi cant, it showed a dose-response association with vaccination coverage (p=0·01). No signifi cant decreases in prevalence or dose-response associations with vaccination coverage were recorded for HPV types 31, 33, and 45, or for HPV types 31, 33, 45, 52, and 58. Finally, a small-but non-signifi cant-increase in non-vaccine high-risk HPV types occurred (RR 1·09, 95% CI 0·98-1·22), which was negatively associated with increasing vaccination coverage (p=0·03).
In addition to vaccination coverage, the use of adjusted or crude RRs emerged as a substantial source of heterogeneity between studies (I² ranged between 50% and 75% for many endpoints; fi gure 3). Notably, the point estimates of adjusted RRs were lower than were the crude RRs for HPV subgroups with substantial postvaccination reductions (ie, HPV types 16 and 18 in 20-24-year-old women; fi gure 3B, and HPV types 16 and 18 and types 31, 33, and 45 in 13-19 year-old girls; fi gure 3A), but were higher than the crude RRs for the other endpoints (fi gure 3).
In girls aged 15-19 years in countries using the quadrivalent vaccine, anogenital warts decreased signifi cantly by 31% (RR 0·69 [95% CI 0·60-0·79]) in the post-vaccination period. A notable dose-response association was recorded between anogenital wart reduction and increase in population-level female vaccination coverage (p=0·0007; fi gure 4A). In the same group, anogenital warts were reduced more substantially (by 61%) in studies with high vaccination coverage than in those with low vaccination coverage (14% reduction; fi gure 5A). In addition to vaccination coverage, years since the start of vaccination emerged as a signifi cant source of heterogeneity (I²=68%, p=0·02; fi gure 5A).
In countries that used the quadrivalent vaccine, nonsignifi cant decreases in anogenital warts were recorded post-vaccination in women 20-39 years of age (11%, RR 0·89 [95% CI 0·79-1·02]) and in boys 15-19 years of age (5%, 0·95 [0·84-1·08]; fi gure 4B, 4C). Again, these reductions showed a signifi cant dose-response association with increased population-level female vaccination coverage (p=0·05 for older women and p=0·005 for young men). Subgroup analyses showed that female vaccination coverage was a main source of heterogeneity (fi gure 5B, 5C). In countries with high female vaccination coverage, anogenital warts were reduced signifi cantly by 32% in women aged 20-39 years (RR 0·68 [95% CI 0·51-0·89]) and by 34% in boys aged 15-19 years (0·66 [0·47-0·91]). No changes in anogenital warts were recorded in men aged 20-39 years in countries using the quadrivalent vaccine (fi gure 4D). 38 Baandrup et al (2013) , 43 and Ali et al (2013); 42 years 3 and 4: Ali et al (2013). 42 For low coverage, the results from the following studies were combined depending on the years of follow-up available: year 1: Leval et al (2013), 41 Kliewer et al (2012), 40 Flagg et al (2013) , 45 Nsouli-Maktabi et al (2013), 47 and Mikolajczyk et al (2013); 46 years 2, 3, and 4: Leval et al (2013), 41 Flagg et al (2013), 45 Nsouli-Maktabi et al (2013), 47 and Bauer et al (2013) . 39 See appendix pp 2-4 for information about vaccination coverage in each study. The only study that assessed population-level changes in anogenital warts following vaccination with the bivalent vaccine 44 reported a small but signifi cant decrease in these warts in girls aged 15-19 years (fi gure 4A). Conversely, a small but signifi cant increase in anogenital warts was recorded in boys aged 15-19 years (fi gure 4C), and no signifi cant eff ect was noted in older people of either sex (fi gure 4B, 4D). Figure 6 shows the changes over time in anogenital warts in studies of the quadrivalent vaccine, with the main sources of heterogeneity taken into consideration. Figure 6A clearly shows a rapid and signifi cant decrease in anogenital warts over time in girls and women younger than 30 years of age in studies with high vaccination coverage. However, in studies with low vaccination coverage (fi gure 6B), the decline was recorded only in girls younger than 20 years of age, and became signifi cant only in the third year after vaccination implementation. A rapid and signifi cant decline in anogenital warts over time also occurred in boys and men younger than 30 years of age in studies with high female vaccination coverage (fi gure 6C). However, in studies with low female vaccination coverage, there was a general pattern of anogenital warts increasing over time, particularly in older men (fi gure 6D).
A signifi cant decrease in high-grade precancerous cervical lesions was recorded in the only study 49 that reported these data for girls aged 15-19 years (RR 0·69, 95% CI 0·66-0·73), but no signifi cant change was recorded in the two studies reporting data in women aged 20 years and older (appendix p 15).
Discussion
This systematic review and meta-analysis, representing more than 140 million person-years of follow-up data from nine high-income countries, reports signifi cant population-level decreases in HPV-related outcomes up to 4 years after the implementation of HPV vaccination programmes. In countries with high vaccination coverage, HPV16 and HPV18 infection, and anogenital warts decreased by more than 60% in girls younger than 20 years of age, starting after the fi rst year of the vaccination programmes. Furthermore, in these countries, our results suggest evidence of vaccine crossprotection and herd eff ects, with signifi cant reductions in HPV31, HPV33, and HPV45 infection in girls younger than 20 years of age, and in anogenital warts in men and older women. In countries with low vaccination coverage, signifi cant reductions were recorded for HPV16 and HPV18 infection and anogenital warts in girls younger than 20 years of age, but no signifi cant reductions were noted for HPV31, HPV33, and HPV45 in this group, or HPV-related outcomes in boys, men, and older women (ie, no indication of cross-protection or herd eff ects). Our fi ndings provide strong evidence that HPV vaccination is highly eff ective and can provide cross-protection outside trial settings, and reinforce the need for early vaccination and high vaccination coverage to maximise populationlevel eff ectiveness and herd eff ects.
Although this meta-analysis is based on time-trend ecological studies, and therefore causality cannot be concluded, several factors strongly suggest that the reported reductions in population-level HPV-related outcomes can be attributed to HPV vaccination. These factors are: the magnitude of the eff ect; the dose-response association between vaccination coverage and eff ect; and consistency, both between the studies included in the review (despite the diff erent methods and settings) and with results from clinical trials and mathematical modelling. First, reductions in HPV types 16 and 18, anogenital warts, and high-grade cervical lesions were large and statistically signifi cant in the target age groups for vaccination (girls <20 years of age). Second, we found a statistically signifi cant positive association between increases in vaccination coverage and reduction in HPV types 16 and 18 infection in girls younger than 20 years of age and anogenital warts in both women and men. Furthermore, reductions in anogenital warts increased over time since vaccination (as the number of vaccinated cohorts increased), especially in youngest age groups with highest vaccination coverage. Third, the results showed consistency between countries with similar levels of vaccination coverage. Furthermore, in the studies in which the vaccine status was available, vaccinated women had signifi cantly lower HPV-related outcomes than did unvaccinated women in the post-vaccination era. [32] [33] [34] 37, 42, [53] [54] [55] [56] Our results are also consistent with data from clinical trials that showed a high vaccine-type effi cacy, 11, 12 and suggested some degree of cross-protection against HPV types 31, 33, and 45, but not against types 52 or 58. 16 However, the higher bivalent cross-protective effi cacy reported in a recent meta-analysis of clinical trial data 16 was not shown in our population-level meta-analysis. Finally, the large herd eff ects reported with high vaccination coverage are consistent with predictions from dynamic models. [20] [21] [22] [23] [24] The studies included in the meta-analysis possess the strengths and weaknesses inherent in ecological studies. They provide a wealth of timely information about the eff ects of HPV vaccination using large study populations, but are especially vulnerable to information bias and confounding (appendix pp 5-9). However, the three most important potential sources of bias and confounding in these studies are likely to underestimate the eff ect of vaccination. First, because of increased awareness of anogenital warts from licensing of the HPV vaccines and the launch of the vaccination programmes, potential exists for confounding related to possible increases in healthseeking behaviours and information bias from increased diagnosis of anogenital warts over time.
Second, most studies had insuffi cient or no information to adequately control for sexual activity, which might have been increasing over time. 43, 57, 58 These limitations might explain the slight increase in the prevalence of non-vaccine high-risk HPV types and anogenital wart consultations in the post-vaccination period within groups with low or no vaccination coverage (eg, women older than 20 years, and men).
Third, information bias might be present as a consequence of masking by HPV type 16 and 18, especially in the pre-vaccine period. 59 That is, by preventing HPV16 and HPV18 infection, vaccination could remove the potential masking eff ect of these types, producing increased detection of non-vaccine types. Conversely, the main potential source of overestimation of vaccination eff ects is present in clinic-based studies that measure the proportion of consultations attributable to anogenital warts in sexual health clinics (appendix pp 7-8). 38, 42 Indeed, changes in the clientele of the clinics between the prevaccination and post-vaccination periods could overestimate the vaccination eff ect on anogenital warts if consultations due to other causes (eg, chlamydia consultations 42 ) became more frequent. Clinic-based studies represent two-thirds of the studies assessing the population-level eff ect of vaccination on anogenital warts in countries with high vaccination coverage, and could partly explain slight reductions in anogenital warts in adult men.
Fourth, the external validity of the studies was generally good (appendix pp 5-9). However, because most studies were undertaken on individuals consulting the health system, the results for the eff ect of HPV vaccination might not be completely generalisable to groups with lower levels of health-seeking behaviour, especially in countries in which the HPV vaccine is delivered in health-care clinics. Finally, in view of the indirect nature of our inferences, our analysis might not have had adequate sensitivity to detect small post-vaccination eff ects (eg, type-replacement, or herd eff ects and cross-protection when vaccination coverage is low).
Our results should be interpreted cautiously because they represent only the short-term population-level eff ects of HPV vaccination programmes. First, the cohorts of vaccinated girls have not yet reached the ages with highest incidence rates of HPV infection, anogenital warts, and cervical lesions (ie, between 20 and 35 years of age). Therefore, the direct and herd eff ects are expected to continue to increase over time as overall population-level vaccination coverage increases.
Second, the existing evidence is insuffi cient to draw conclusions about the existence of net type-replacement (eg, no signifi cant increase in the prevalence of high-risk non-vaccine HPV types in groups with the highest vaccination coverage), which could be because no typereplacement is occurring, or partly a consequence of the short follow-up time or dilution of type-specifi c changes by grouping HPV types.
Third, the time horizon was too short to examine waning of vaccine effi cacy. However, randomised controlled trials have shown no signs of waning vaccine effi cacy after 9·5 years of follow-up. 60 Fourth, in view of the long lag time between infection and cancer, no direct evidence of the eff ect of vaccination on HPV-related cancers is currently available. However, since HPV infection is the cause-and high-grade precancerous cervical lesions the precursors-of cervical cancer, these intermediate outcomes have been judged acceptable proxies for effi cacy against cervical cancer by regulatory bodies worldwide. [61] [62] [63] [64] Nevertheless, one should be careful in using reductions in precancerous cervical lesions from screening databases as proxies for cervical cancer because they might represent changes in screening recom mendations and participation, and they are not HPV type-specifi c. Additionally, surveillance studies based on cervical screening registries could overestimate the population-level eff ect of HPV vaccination, if vaccine uptake is higher in women who undergo screening. [65] [66] [67] [68] Finally, as previously shown, trends in HPV types 6 or 11-related disease (eg, anogenital warts) are a poor proxy of change in HPV types 16 and 18 and related diseases (eg, cervical cancer). 69 This is because HPV6 and HPV11 will be easier to eliminate and control through vaccination than HPV16 and HPV18 because of their shorter durations of infectiousness and lower transmissibility.
Our overall fi ndings are likely generalisable to highincome countries, since most of the heterogeneity between countries disappeared once results were stratifi ed by vaccination coverage and age, and given similarities in sexual behaviour, 58 HPV type distribution, 70, 71 age profi le of HPV prevalence, 72 and cervical cancer incidence between high income countries. 73 However, precise estimates of population-level eff ect will vary between countries according to their programmatic specifi cities, such as the characteristics of catch-up campaigns.
Our results should be extrapolated to low-income and middle-income countries with caution because all studies in the meta-analysis were from high-income countries and substantial diff erences exist between these countries and low-income and middle-income countries in sexual behaviour, 58 HPV epidemiology, 72, 73 and potential cofactors of HPV infection and disease, such as high HIV prevalence. 74 However, no evidence exists to suggest that vaccine effi cacy would be lower in low-income and middle-income countries, especially because the vaccine has been shown safe and immunogenic in women with HIV infection. 75 On the other hand, herd eff ects could diff er in low-income and middle-income countries with very diff erent population-level sexual behaviour (eg, increased mixing between older men and younger women, and more concurrency in partnerships). Even in the unlikely scenario that there would be no herd eff ects in such countries, a recent global modelling study (PRIME) 19 has shown that HPV vaccination would be highly cost eff ective, in view of the very high cervical cancer incidence and mortality in these countries, This fi rst meta-analysis of the population-level eff ect of HPV vaccination programmes shows compelling evidence of a strong and statistically signifi cant dose-response association between HPV vaccination coverage and reductions in HPV16 and HPV18 infection and anogenital warts in cohorts of girls and women targeted for vaccination. Additionally, our study provides the fi rst evidence of a dose-response association between female vaccination coverage and reduction of anogenital warts in older women and men.
Our results have important policy implications. The sharpest declines in HPV-related outcomes in both male and female participants were recorded in countries with school-based vaccine delivery (eg, the UK, Australia, and New Zealand), which suggests that this strategy helps faster rollout and higher vaccination coverage than nonschool-based vaccine programmes. Our study also shows population-level data supporting clinical trial evidence of HPV vaccine cross-protection against HPV types 31, 33, and 45, although no dose-response with vaccination coverage was recorded.
In conclusion, the results of this study are very promising for the long-term population-level eff ect of HPV vaccination programmes on cervical cancer and other HPV-related diseases. However, we must continue to monitor and evaluate HPV vaccination programmes to confi rm these results, and we need to remain vigilant for evidence of potential waning effi cacy, type-replacement, or lower vaccination coverage in groups at greater risk of HPV-related cancers.
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